|Title||Donor-Derived Metastatic Melanoma and Checkpoint Inhibition|
|Publication Type||Journal Article|
|Year of Publication||2017|
|Authors||Boyle SM, Ali N, Olszanski AJ, Park DJ, Xiao G, Guy S, Doyle AM|
Donor-derived malignancy, particularly melanoma, is a rare but known complication of organ transplantation. Here we describe a case of metastatic melanoma in a deceased-donor kidney transplant recipient. After diagnosis, the patient was successfully treated with cessation of immunosuppression, explantation of the renal allograft, and novel melanoma therapies, including the mutation-targeted agents dabrafenib and trametinib and the immune checkpoint inhibitor nivolumab. These 2 new classes of melanoma therapy have revolutionized the course of metastatic melanoma, altering it from one of nearly certain mortality to one of potential cure. This case reviews the mechanisms of action of these therapies and reports our experience with them in the rare setting of donor-derived melanoma in a dialysis-dependent patient.
|Alternate Journal||Transplant Proc|
|Notify Library Reference ID||4704|